SPI Pharma And Oregon Freeze Dry Form Alliance

Source: Oregon Freeze Dry, Inc.

SPI Pharma expands its capabilities to offer Microencapsulation and Lyophilization technologies to the global Pharmaceutical market.

Albany, OR — SPI Pharma, a leading manufacturer and supplier of Excipients, Delivery systems and Antacid actives to the global Pharmaceutical industry has added, through strategic alliances, two complementary and enabling technologies to its portfolio.

Taste-masking / Controlled release: SPI Pharma (SPI) and Particle & Coating Technologies (PCT) have signed an exclusive licensing agreement giving SPI global exclusivity to manufacture and market, microencapsulated actives using PCT's patented and proprietary technologies. Combining PCT's proven expertise in the selection of coating materials and efficient processes, with SPI's know-how in Formulation development and testing along with cGMP manufacturing, will enable SPI to offer a broad base of Pharmaceutical solutions.

Lyophilization: SPI Pharma (SPI) and Oregon Freeze Dry (OFD) have signed an exclusive licensing agreement giving SPI global exclusivity to market OFD's patented Lyophilization technology to the Pharmaceutical market. OFD has over 40 years of designing, installing and operating Lyophilization systems. Combining their cGMP bulk processing and packaging capability with SPI's Drug development & testing will provide a total solution to SPI's global customers.

As a result of these strategic alliances, SPI Pharma will be able to provide a full range of services for QUICK DISSOLVE, CHEWABLE and CONTROLLED RELEASE formulations.

SOURCE: Oregon Freeze Dry, Inc.